Last reviewed · How we verify
IM862
IM862 is an immunomodulatory agent that enhances immune function through interleukin-2 (IL-2) pathway activation.
IM862 is an immunomodulatory agent that enhances immune function through interleukin-2 (IL-2) pathway activation. Used for Metastatic renal cell carcinoma, Metastatic melanoma.
At a glance
| Generic name | IM862 |
|---|---|
| Sponsor | Cytran |
| Drug class | Immunomodulatory peptide |
| Target | IL-2 pathway / T-cell activation |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IM862 is a synthetic peptide that acts as an immune stimulant, primarily working through IL-2 signaling to enhance T-cell proliferation and natural killer cell activity. It was developed to boost anti-tumor immune responses and has been investigated for its ability to potentiate immune-mediated tumor control in cancer patients.
Approved indications
- Metastatic renal cell carcinoma
- Metastatic melanoma
Common side effects
- Flu-like symptoms
- Fatigue
- Fever
- Injection site reactions
Key clinical trials
- IM-862 in Treating Patients With Recurrent Ovarian Cancer (PHASE1)
- Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer (PHASE2)
- Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer (PHASE2)
- Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IM862 CI brief — competitive landscape report
- IM862 updates RSS · CI watch RSS
- Cytran portfolio CI